Human Genome Sciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Human Genome Sciences, Inc.
B+L’s novel therapy for a subset of dry eye disease hits both sign and symptom endpoints in the first of two Phase III studies. The product could add value to a planned spinout.
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
Plus deals involving Scynexis/Hansoh, Cend/Qilu, Apollomics/Edison, Apollomics/Iterion, Apollomics/Nuance, Aerami/Chance, Antibe/Nuance, Ildong/Arbormed
There have been lots of twists and turns on the development path for Inrebic which is now the second JAK inhibitor to be approved in the EU for MF since the blockbuster Jakavi was cleared in 2012.